Opinions
Jean-Francois Tardif
Diagnocure Inc.
CUR-T
TOP PICK
Dec 03, 2004
Has a test on the market for bladder testing for cancer. Now working with a US company, Gen-Probe, to develop a prostrate diagnostic test for the US and world markets. Tests are 90% accurate compared to the PSA tests which are only right once out of four times. Have also just announced testing for lung cancer with high accuracy figures.
$5.860
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.